These findings collectively suggest that the icotinib-induced upregulation of CBL-b is mediated by the inhibition of NF-κB, and that CBL-b plays a role in the sensitivity of EGFR-mutated NSCLC cells to icotinib. Here, EGFR is linked to non-small cell lung carcinoma.